Cargando…

Probing gut‐brain links in Alzheimer's disease with rifaximin

Gut‐microbiome‐inflammation interactions have been linked to neurodegeneration in Alzheimer's disease (AD) and other disorders. We hypothesized that treatment with rifaximin, a minimally absorbed gut‐specific antibiotic, may modify the neurodegenerative process by changing gut flora and reducin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suhocki, Paul V., Ronald, James S., Diehl, Anna Mae E., Murdoch, David M., Doraiswamy, P. Murali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804600/ https://www.ncbi.nlm.nih.gov/pubmed/35128026 http://dx.doi.org/10.1002/trc2.12225

Ejemplares similares

Gut–microbiota–microglia–brain interactions in Alzheimer’s disease: knowledge-based, multi-dimensional characterization
por: Wang, QuanQiu, et al.
Publicado: (2021)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
por: Ponziani, Francesca Romana, et al.
Publicado: (2017)

Effects of Rifaximin on Luminal and Wall-Adhered Gut Commensal Microbiota in Mice
por: Ferrer, Marina, et al.
Publicado: (2021)

PET Imaging of Tau Pathology in Alzheimer’s Disease and Tauopathies
por: James, Olga G., et al.
Publicado: (2015)

Diverticular Disease and Rifaximin: An Evidence-Based Review
por: Piccin, Anna, et al.
Publicado: (2023)

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies
por: Hong, Chien-Tai, et al.
Publicado: (2022)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Science to Practice: Translating Automated Brain MRI Volumetry in Alzheimer’s Disease from Research to Routine Diagnostic Use in the Work-Up of Dementia
por: Rathakrishnan, Bharath Gopal, et al.
Publicado: (2014)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

When Mars Versus Venus is Not a Cliché: Gender Differences in the Neurobiology of Alzheimer’s Disease
por: Lin, Katherine Amy, et al.
Publicado: (2015)

Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
por: Cianci, Rossella, et al.
Publicado: (2014)

Underrepresentation of African-Americans in Alzheimer's Trials: A Call for Affirmative Action
por: Shin, Jaewook, et al.
Publicado: (2016)

An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin
por: Xenofontos, Eleni, et al.
Publicado: (2022)

Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species
por: Yukawa‐Muto, Yoshimi, et al.
Publicado: (2022)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Implication of Gut Microbiota in Nonalcoholic Fatty Liver Disease
por: Boursier, Jerome, et al.
Publicado: (2015)

Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats
por: Zhang, Jindong, et al.
Publicado: (2023)

The role of rifaximin in the treatment and chemoprophylaxis of travelers’ diarrhea
por: Koo, Hoonmo L, et al.
Publicado: (2009)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Rifaximin for Pertuzumab-Related GI Toxicities
por: Soyano, Aixa E., et al.
Publicado: (2017)

Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease
por: Petrella, Jeffrey R., et al.
Publicado: (2019)

Brain atrophy rates in first degree relatives at risk for Alzheimer's
por: Lampert, Erika J., et al.
Publicado: (2014)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites
por: Luo, Mei, et al.
Publicado: (2023)

Expanding the scope of health disparities research in Alzheimer's disease and related dementias: Recommendations from the “Leveraging Existing Data and Analytic Methods for Health Disparities Research Related to Aging and Alzheimer's Disease and Related Dementias” Workshop Series
por: Akushevich, Igor, et al.
Publicado: (2023)

IMPACT OF CALORIE RESTRICTION ON PLASMA ALZHEIMER’S DISEASE BIOMARKERS IN HEALTHY YOUNG AND MIDDLE-AGED ADULTS
por: Parker, Daniel, et al.
Publicado: (2022)

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials
por: Doraiswamy, P. Murali, et al.
Publicado: (2018)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis
por: Shen, Bo, et al.
Publicado: (2008)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
por: Rezigh, Alec B., et al.
Publicado: (2018)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Data-driven causal model discovery and personalized prediction in Alzheimer's disease
por: Zheng, Haoyang, et al.
Publicado: (2022)

Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy
por: De Vincentis, Antonio, et al.
Publicado: (2021)

Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer’s disease
por: Gamberger, Dragan, et al.
Publicado: (2017)

Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management
por: Maconi, Giovanni
Publicado: (2017)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
por: Sousa, Ana L., et al.
Publicado: (2019)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tom0fs4bo3mc2uu91nvdri0dce